This profile was last updated on .
Is this you? Claim your profile.
(183 Total References)
ACTC CEO Gary ...
ACTC CEO Gary Rabin recently presented at the 14th Annual Rodman & Renshaw Global Investment Conference.
As one of the few companies engaged in embryonic stem cell research, ACTC has generated significant interest among investors.
However, the field of stem cell research remains controversial.
commented on U.S. Appeals' Court's dismissal ruling in case challenging federal funding of embryonic stem cell research.
CEO Rabin said that the court ruling should be of considerable benefit to the company and its embryonic stem cell-based clinical programs.
said that the ruling effectively removes major speed bumps for the National Institutes of Health
in terms of approving the several stem cell lines that ACTC
has submitted for their consideration for funding.
also said that the ruling removes a great deal of ambiguity that has hampered legislative attempts to provide an efficient mechanism for federal funding of hESC research.
added that the path for legislators to enact such legislation has now been cleared and in that case ACTC
is optimistic that there could be encouraging new developments in the legislative arena, as well, in coming months.
To See Again (Advanced Cell Technology, Inc) - Stock Pick 101
According to ACTC, the stem cells for that study were derived from an embryo created in a fertility clinic by a couple that chose not to use it to create a pregnancy, said Gary Rabin, chief executive officer of Advanced Cell Technology, who said the couple donated the embryo to the company.
Stem Cell News | é¦™æ¸¯å¹¹ç´°èƒžä¸å¿ƒ - Part 5
Interview with Gary Rabin of Advanced Cell Technology (ACTC ...
ACTC | PennyStocksTribune.com
"ACT is now the first company to receive FDA clearance for two hESC trials, and is now a true translational leader in the field of regenerative medicine," said Gary Rabin, Interim Chairman and CEO of ACTC in a statement.
ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company's chairman and CEO, Gary Rabin, will be presenting at the 2011 World Stem Cell Summit on Wednesday, Oct. 5, at the Pasadena Convention Center in Pasadena, Calif.
Mr. Rabin's presentation will provide an update on the company's two ongoing human clinical trials in the U.S. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt's Macular Dystrophy using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
will also discuss plans for the first human embryonic stem cell clinical trial in Europe.
The company recently received regulatory clearance to initiate the trial.
After the conference, an archived copy of Mr. Rabin's
PowerPoint presentation will be available on the "conference presentations section" of ACT's